Grants and Contracts Details
Description
Inotropic support for hearts progressing towards failure represents an unmet need. Direct attempts to improve
systolic function by activating β-adrenergic receptor (β-AR) signaling increases associated risk of heart failure
and death. Calcitropes (agents influencing Ca2+ handling) that bypass β-AR signaling are not necessarily
proarrhythmic. Our working global hypothesis based on our recent and ongoing work studying RAD regulation
of the L-type Ca2+ channel (LTCC) is that bypassing β-AR signaling to increase Ca2+-induced Ca2+ release (CICR)
provides safe, stable gain of function to counter heart failure progression. In this application we focus on the
mechanisms of Rad – LTCC interactions as a novel means to instill inotropic support to the heart. The LTCC is
a macromolecular hub that integrates multiple signaling pathways including protein kinase A (PKA) and Ca2+-
calmodulin kinase II (CaMKII). RAD is a member of the RGK family of monomeric G-proteins. RAD binds to
auxiliary CaVβ2 and CaV1.2, the pore-forming subunit of the LTCC. Deletion, or phosphorylation of RAD causes
LTCC current (ICa,L) modulation and facilitation. Modulation of ICa,L is commonly observed after β-AR signaling to
activate PKA; facilitation is caused by CaMKII activation. In Specific Aim 1 we will dissect how RAD integrates
each of these signaling pathways using a combination of pharmacological and genetic approaches. In Specific
Aim 2 we will explore RAD – CaV1.2 structure-function using knock-in models of genetically modified mice that
allow us to explore RAD – LTCC effects retaining native stoichiometry of the LTCC heteromultimeric protein
complex. Specific Aim 3 explores RAD – LTCC interplay as an approach to attenuate progression of heart failure.
To achieve these goals, we will integrate findings among Aims using in vivo, ex vivo and cellular/molecular
approaches in animal models. Ex vivo human heart slices will be tested to evaluate the translational potential of
RAD – LTCC regulation in heart health and disease.
| Status | Active |
|---|---|
| Effective start/end date | 7/31/23 → 5/31/27 |
Funding
- National Heart Lung and Blood Institute: $1,892,104.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.